Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-324-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- An assessment of toxicokinetics, based on available data, in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006 (REACH)
- Type of information:
- other: Desk-based assessment
- Adequacy of study:
- key study
- Study period:
- Not applicable
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- An assessment of toxicokinetics, based on available data, in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006 (REACH)
- GLP compliance:
- no
- Details on species / strain selection:
- No animals were used in this desk-based assessment.
- Details on test animals or test system and environmental conditions:
- Not applicable
- Details on exposure:
- No animals were used in this desk-based assessment.
- Duration and frequency of treatment / exposure:
- No animals were used in this desk-based assessment.
- No. of animals per sex per dose / concentration:
- No animals were used in this desk-based assessment.
- Positive control reference chemical:
- No animals were used in this desk-based assessment.
- Details on study design:
- Not applicable
- Details on dosing and sampling:
- Not applicable
- Statistics:
- Not applicable
- Preliminary studies:
- Not applicable
- Details on absorption:
- The molecular weight of both constituents is low i.e. < 200 g/mol, it’s n-octanol/water partition coefficient is 4.6 for constituent I and 3.2 for constituent II, its water solubility is 1.71mg/L for constituent I and 101 mg/L for constituent II and vapour pressure of 58.6 Pa for constituent I and 14.3 Pa for constituent II are suggestive of favourable absorption via all routes. Although these properties make uptake from the dermal route possible, the surface tension (assumed >60 mN/m) could restrict transfer between the stratum corneum and the epidermis and therefore overall uptake via this route is limited. This is demonstrated by the lack of significant systemic and local toxicity from in vivo sensitisation study on the test item. Absorption from the gastro-intestinal tract and the respiratory tract epithelium: Oral absorption of the test item is mainly via passive diffusion to into portal circulation with delivery into the liver i.e. first pass metabolism and relative high pulmonary uptake. For example, d-Limonene is demonstrated to be well absorbed via the lungs in humans (i.e. u 70%) and the gastro-intestinal tract has been reported at up to 80% in humans as well as experimental animals.
- Details on distribution in tissues:
- The substance has physico-chemical properties that mean the test item can easily pass through aqueous pores or be carried through the epithelial barrier by the bulk passage of water into the liver. This will limit distribution of the parent compound systemically and limited half-life of the parent compound in blood plasma. A wide distribution of the substance via inhalation is expected as it can easily be taken up into circulatory system. For example, d-limonene and its metabolites has been shown to be detectable in kidney, liver, lung, serum and many other tissues, with higher concentrations detected in adipose tissue and mammary gland than in less fatty tissue.
- Details on excretion:
- The n-Octanol/water partition coefficient (log Pow of 3.2 – 4.6) and supporting bioaccumulation data (BCF <2,000) suggest accumulation of this substance in fatty tissues after absorption from gastro-intestinal tract is not significant, the substance could enter circulation via lymphatic system. Based on the molecular structure and solubility, excretion into urine as conjugated metabolites is assumed to be a preferred route of elimination. A small percentage of the parent compound may also be excreted via urine and faces. Elimination is assumed to be rapid, therefore no potential for bioaccumulation is to be expected, as demonstrated by the half-life of d-limonene in human i.e. about 12- 24 hours. The observed clinical changed in kidney would confirms urine as the most probably route of excretion. About 25-30% of an oral dose of d-limonene in humans eliminated in urine as d-limonene-8,9-diol and its glucuronide and about 7-11% eliminated as perillic acid and its metabolites.
- Metabolites identified:
- not measured
- Details on metabolites:
- Metabolism is mainly through the liver via phase I and II enzymes as demonstrated by centrilobular hepatocyte hypertrophy in the liver in both sexes. For constituent I (d-limonene); oxygenation of parent compound resulting in acidic and alcohol metabolites such as perillic acid, dihydroperillic acid, and limonene-1-,2-diol. These will be conjugated by phase II enzymes forming glucuronides conjugates. In circulatory system, d-limonene is known to induce unique nephropathy syndrome in rats after subacute or chronic exposure which is associated with α2u globulin accumulation in hyaline droplets, a condition not relevant to human. This is supported by the clinical observations slight increase in the incidence and severity of cortical tubular basophilia and changes in renal functions such as acidic urine with high urea and uniary chlorine, triglyceride, total creatinine and total potassium. For constituent II, metabolism mainly involve reduction of the ketone by carbonyl reductases to generate a secondary cyclic alcohol which may either be converted back to parent compound or conjugated with glucuronic acid and excreted in the bile and urine. Another route to consider is the microbial metabolism where the cyclic ketones undergoing oxidation forming a cyclic lactone which is further metabolized via ester hydrolysis forming hydroxyl carboxylate derivatives which would undergo phase II metabolism and eliminated via urine.
- Conclusions:
- The substance has physico-chemical properties with favourable ADME. Exposure from oral and inhalation routes are most favourable and therefore the substance is expected to be widely distributed especially via inhalation exposure. Based on the log Pow of 3.2 – 4.6 and BCF <2,000, bioaccumulation is not significant and elimination is rapid as demonstrated by half-life of 12-24 hours. The lack of systemic and local toxicity observed following in vivo sensitisation study shows that systemic bioavailability of this substance may be limited via dermal exposure. The clinical signs observed following oral sub-acute exposure support oral absorption of the test item and clinical signs reported in liver and kidney are demonstrative of distribution, biotransformation and elimination of the test item. Furthermore, full reversibility of clinical signs observed during recovery period following the repeated exposure of the test item in rats demonstrate no bioaccumulation and rapid elimination of the test item. It can be concluded that the toxicokinetic of the test item does not pose significant toxicological concern based on available data.
- Executive summary:
A desk-based assessment of the toxicokinetics of the substance Reaction Mass of (4R)-4-isopropenyl-1-methylcyclohexene and (4R)-4-(2-methoxypropan-2-yl)-1-methylcyclohexene (test item), in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006 (REACH). The substance has physico-chemical properties with favourable ADME. Exposure from oral and inhalation routes are most favourable and therefore the substance is expected to be widely distributed especially via inhalation exposure. Based on the log Pow of 3.2 – 4.6 and BCF <2,000, bioaccumulation is not significant and elimination is rapid as demonstrated by half-life of 12-24 hours. The lack of systemic and local toxicity observed following in vivo sensitisation study shows that systemic bioavailability of this substance may be limited via dermal exposure. The clinical signs observed following oral sub-acute exposure support oral absorption of the test item and clinical signs reported in liver and kidney are demonstrative of distribution, biotransformation and elimination of the test item. Furthermore, full reversibility of clinical signs observed during recovery period following the repeated exposure of the test item in rats demonstrate no bioaccumulation and rapid elimination of the test item. It can be concluded that the toxicokinetic of the test item does not pose significant toxicological concern based on available data.
Reference
Description of key information
Toxicokinetics Assessment: no bioaccumulation potential; desk-based assessment in accordance with Annex VIII, Section 8.8.1 of REACH; Anon. (2017)
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
A desk-based assessment of the toxicokinetics of the substance Reaction Mass of (4R)-4-isopropenyl-1-methylcyclohexene and (4R)-4-(2-methoxypropan-2-yl)-1-methylcyclohexene (test item), in accordance with Annex VIII, Section 8.8.1 of Regulation (EC) No 1907/2006 (REACH). The substance has physico-chemical properties with favourable ADME. Exposure from oral and inhalation routes are most favourable and therefore the substance is expected to be widely distributed especially via inhalation exposure. Based on the log Pow of 3.2 – 4.6 and BCF <2,000, bioaccumulation is not significant and elimination is rapid as demonstrated by half-life of 12-24 hours. The lack of systemic and local toxicity observed following in vivo sensitisation study shows that systemic bioavailability of this substance may be limited via dermal exposure. The clinical signs observed following oral sub-acute exposure support oral absorption of the test item and clinical signs reported in liver and kidney are demonstrative of distribution, biotransformation and elimination of the test item. Furthermore, full reversibility of clinical signs observed during recovery period following the repeated exposure of the test item in rats demonstrate no bioaccumulation and rapid elimination of the test item. It can be concluded that the toxicokinetic of the test item does not pose significant toxicological concern based on available data.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.